NovalGen Ltd.
Novalgen is a clinical-stage company revolutionizing the immunology landscape with its innovative autoregulation technology. Focused on the next generation of multi-specific antibodies, it aims to generate transformative outcomes in autoimmune, oncological, and other immunological disorders. The company emphasizes serving patients, fostering a dedicated and innovative team, and pioneering next-generation immunotherapies.
Industries
Nr. of Employees
small (1-50)
NovalGen Ltd.
Products
Clinical-stage bispecific T-cell engager (pipeline candidate)
A next-generation bispecific T-cell engager advanced into first-in-human studies intended to engage T cells against tumour targets; progressed via external manufacturing partnerships.
Pipeline of multi-specific antibody candidates (preclinical and clinical-stage)
A portfolio of multi-specific antibody therapeutics engineered with self-regulating design principles, spanning preclinical work and clinical-stage development.
Clinical-stage bispecific T-cell engager (pipeline candidate)
A next-generation bispecific T-cell engager advanced into first-in-human studies intended to engage T cells against tumour targets; progressed via external manufacturing partnerships.
Pipeline of multi-specific antibody candidates (preclinical and clinical-stage)
A portfolio of multi-specific antibody therapeutics engineered with self-regulating design principles, spanning preclinical work and clinical-stage development.
Services
Partnering with academic centres, research organisations and CMOs to advance preclinical candidates into clinical studies and to access specialised expertise.
Development of manufacturing processes and downstream purification workflows compatible with cGMP production to support clinical supply of antibody-based molecules.
Operational support for first-in-human and early-phase clinical studies including trial execution and clinical data generation.
Partnering with academic centres, research organisations and CMOs to advance preclinical candidates into clinical studies and to access specialised expertise.
Development of manufacturing processes and downstream purification workflows compatible with cGMP production to support clinical supply of antibody-based molecules.
Operational support for first-in-human and early-phase clinical studies including trial execution and clinical data generation.
Expertise Areas
- Multi-specific antibody engineering
- Immuno-oncology (T-cell engager development)
- Translational medicine and early-phase clinical development
- Biologics CMC and downstream process development
Key Technologies
- Multi-specific/bispecific antibody constructs
- Autoregulation / self-regulating biologic design
- Bispecific T-cell engager constructs
- Half-life extension strategies for biologics